EyeMacular Regeneration, Inc. — SEC Form D Filing

EyeMacular Regeneration, Inc. filed an SEC Form D on September 24, 2026, reporting $2.87M raised in Medical Devices.

Form D filing details

Filing
SEC Form D
Filing date
September 24, 2026
Amount reported
$2.87M
Round stage
Pre-Seed
Industry
Medical Devices
Website
https://www.eyemacregen.com/

What the company does

Securities: Equity. Revenue: No Revenues. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Patients with advanced age-related macular degeneration (AMD) experience permanent vision loss and have exhausted existing treatment options, including intravitreal injections, leaving them with no current therapeutic solutions.

Solution

EyeMac Regen develops specialized surgical instruments and platform technologies, including a permanently implantable scaffold called Macular O-Rings (MORs), to support regenerative tissue in the submacular space through a novel approach called Incisional Choroidal Surgery (ICS).

Why now

There is a persistent and growing unmet medical need for effective treatments for advanced, end-stage macular degeneration, especially as the global population ages and existing therapies become insufficient for all patients.

Verdict

Investors said yes due to the significant unmet medical need in end-stage AMD and the proposed surgical implant's novelty for a population out of options. This cleared because it targeted a high-stakes, irreversible condition with a hard-tech solution, not because it promised a low-friction entry into an adjacent, crowded ophthalmology market. They implicitly bet on the scientific and clinical validation of a complex surgical approach, accepting the high regulatory and development risk associated with medical devices for novel procedures. The limited upside stemmed from the long development cycles and the narrow patient population, which restricts immediate market penetration compared to broader diagnostic or earlier-stage treatment platforms.

Source: SEC EDGAR Form D filing